Methodological Challenges and Preferred Approaches for the Economic Evaluation of CAR T Therapies: Evidence Review and Expert Consensus from NICE Appraisals

This publication has 21 references indexed in Scilit:

• Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review
  PharmacoEconomics - Open, 2025
• Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria
  PharmacoEconomics, 2025
• Recommendations on the Use of Structured Expert Elicitation Protocols for Healthcare Decision Making: A Good Practices Report of an ISPOR Task Force
  Value in Health, 2024
• Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review
  Value in Health, 2024
• Improved outcomes of large B‐cell lymphoma patients treated with CD19 CAR T in the UK over time
  British Journal of Haematology, 2023
• Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health
  Bulletin du Cancer, 2021
• Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  New England Journal of Medicine, 2019
• Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
  New England Journal of Medicine, 2017
• Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
  Value in Health, 2012
• The qualitative content analysis process
  Journal of Advanced Nursing, 2008